Eight DCI Scientists Among World's Most Cited
Published
From the Duke Cancer Institute archives. Content may be out of date.
Duke Cancer Institute members Robert Lefkowitz, MD (in Biology and Biochemistry), Barton Haynes, MD (in Microbiology), Charles Gersbach, PhD (in Biology and Biochemistry), Jason Locasale, PhD (in Cross-Field), and Christopher Newgard, PhD (in Cross-Field) have once again made the list of the world's Most Cited Scientists according to the 2022 Web of Science citation index by Clarivate. New on the list this year from DCI are John F. Rawls, PhD (in Cross-Field), and Quinn T. Ostrom, PhD, MPH, MA (Neuroscience and Behavior).
The annual global list of nearly 7,000 authors includes 30 Duke researchers.
READ the Duke Research Blog to see who else at Duke made the list
**UPDATE Dec.7, 2022: We have learned that DCI member Scott Antonia, MD, PhD (in the Clinical Medicine category) is also on this list of now 33 Duke researchers. When a current Duke faculty member is most cited for a paper they authored at another institution, Clarivate doesn't provide that name to us. We are happy to add to this list, however, when a current Duke faculty member receives direct notification from Clarivate.
Written By
Julie Poucher Harbin
Senior Writer, Duke Cancer Institute
Related News
New Study Identifies Immune Cell Interactions Associated with Survival in Brain Metastases
A Duke-led study published in iScience provides new insights into the tumor microenvironment of brain metastases, identifying distinct macrophage populations associated with patient survival and highlighting potential targets for future therapeutic intervention.Brain metastases remain a significant clinical challenge across multiple tumor types, including breast cancer, lung cancer, and melanoma. Despite advances in systemic therapies and local treatment approaches, outcomes remain poor for many patients, underscoring the need for a deeper understanding of the biological mechanisms driving disease progression.Using an integrated multi-omic approach, investigators analyzed 23 human brain metastasis specimens through single-nucleus RNA sequencing and spatial transcriptomic profiling. The study leveraged these complementary technologies to characterize cellular heterogeneity within the tumor microenvironment and define spatial relationships between immune and tumor cell populations.The analysis revealed substantial macrophage heterogeneity and demonstrated that macrophage-associated transcriptional programs differ significantly between patients with favorable and unfavorable survival outcomes. Specifically, inflammatory macrophage populations localized at the tumor boundary were associated with improved survival, while macrophage populations characterized by extracellular matrix remodeling signatures and TGFβ1 expression were associated with poorer outcomes.These findings suggest that distinct macrophage subtypes may play context-dependent roles in brain metastatic progression, functioning as either tumor-restrictive or tumor-supportive components of the microenvironment. The results further emphasize the importance of spatial cellular organization in shaping disease biology and clinical outcomes.Importantly, the study extends current understanding of immune-tumor interactions in brain metastases by linking specific macrophage subtypes and locations within the tumor ecosystem to survival-associated phenotypes. The identification of these distinct cellular programs may provide a framework for the development of novel therapeutic strategies aimed at modulating macrophage function or disrupting protumor signaling networks within the metastatic niche.As the incidence of brain metastases continues to increase and therapeutic resistance remains a critical barrier to long-term disease control, these findings represent an important step toward the development of more precise, microenvironment-directed treatment approaches. Further investigation will be needed to validate these observations and assess their translational potential in prospective clinical studies.This work was a joint research collaboration among Duke Center for Brain and Spine Metastasis (DCBSM) members: Dr. Ann Marie Pendergast (Department of Pharmacology and Cancer Biology, Duke University School of Medicine), Dr. Carey Anders (Department of Medicine, Division of Medical Oncology), and Dr. Simon Gregory (Department of Neurosurgery, and Duke Molecular Physiology Institute), and first-author Dr. Aaditya Khatri (Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Duke University School of Medicine).
Related News
New Study Identifies Immune Cell Interactions Associated with Survival in Brain Metastases
A Duke-led study published in iScience provides new insights into the tumor microenvironment of brain metastases, identifying distinct macrophage populations associated with patient survival and highlighting potential targets for future therapeutic intervention.Brain metastases remain a significant clinical challenge across multiple tumor types, including breast cancer, lung cancer, and melanoma. Despite advances in systemic therapies and local treatment approaches, outcomes remain poor for many patients, underscoring the need for a deeper understanding of the biological mechanisms driving disease progression.Using an integrated multi-omic approach, investigators analyzed 23 human brain metastasis specimens through single-nucleus RNA sequencing and spatial transcriptomic profiling. The study leveraged these complementary technologies to characterize cellular heterogeneity within the tumor microenvironment and define spatial relationships between immune and tumor cell populations.The analysis revealed substantial macrophage heterogeneity and demonstrated that macrophage-associated transcriptional programs differ significantly between patients with favorable and unfavorable survival outcomes. Specifically, inflammatory macrophage populations localized at the tumor boundary were associated with improved survival, while macrophage populations characterized by extracellular matrix remodeling signatures and TGFβ1 expression were associated with poorer outcomes.These findings suggest that distinct macrophage subtypes may play context-dependent roles in brain metastatic progression, functioning as either tumor-restrictive or tumor-supportive components of the microenvironment. The results further emphasize the importance of spatial cellular organization in shaping disease biology and clinical outcomes.Importantly, the study extends current understanding of immune-tumor interactions in brain metastases by linking specific macrophage subtypes and locations within the tumor ecosystem to survival-associated phenotypes. The identification of these distinct cellular programs may provide a framework for the development of novel therapeutic strategies aimed at modulating macrophage function or disrupting protumor signaling networks within the metastatic niche.As the incidence of brain metastases continues to increase and therapeutic resistance remains a critical barrier to long-term disease control, these findings represent an important step toward the development of more precise, microenvironment-directed treatment approaches. Further investigation will be needed to validate these observations and assess their translational potential in prospective clinical studies.This work was a joint research collaboration among Duke Center for Brain and Spine Metastasis (DCBSM) members: Dr. Ann Marie Pendergast (Department of Pharmacology and Cancer Biology, Duke University School of Medicine), Dr. Carey Anders (Department of Medicine, Division of Medical Oncology), and Dr. Simon Gregory (Department of Neurosurgery, and Duke Molecular Physiology Institute), and first-author Dr. Aaditya Khatri (Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Duke University School of Medicine).